Literature DB >> 27435523

Two infants with tuberculid associated with Kawasaki disease.

Hiroko Yamada1, Haruka Ohta1, Shunji Hasegawa1, Yoshihiro Azuma1, Masanari Hasegawa2, Ryo Kadoya3, Noriko Ohbuchi3, Yuji Ohnishi1, Seigo Okada1, Madoka Hoshide1, Shouichi Ohga1.   

Abstract

Bacille de Calmette et Guerin (BCG) is the only licensed tuberculosis vaccine to prevent severe tuberculosis. The adverse events of BCG vaccination, including local reactions, lymphadenitis, osteomyelitis, tuberculid, and disseminated infection, have been reported. Two infants presented erythema at the inoculation site of BCG after the resolution of Kawasaki disease (KD). They received BCG vaccination 1 week and 6 weeks before the KD onset, respectively. Intravenous immunoglobulin improved the KD activity, however the skin rash of BCG inoculation site extended to the face and extremities days 24 and 10 after the KD onset, respectively. Both bacteriological study and interferon-γ release assay were negative for Mycobacterium tuberculosis infection. These patients were diagnosed as having tuberculid after KD. The skin lesions gradually disappeared without antibiotic therapy over 2 months. The development of tuberculid in these patients might be associated with the remnant immune activation of KD.

Entities:  

Keywords:  Bacille de Calmette et Guerin (BCG); Kawasaki disease; children; tuberculid; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27435523      PMCID: PMC5137533          DOI: 10.1080/21645515.2016.1208329

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


Introduction

Bacille de Calmette et Guerin (BCG) vaccine is the only available vaccine for the prevention of severe and disseminated tuberculosis. Local reactions, lymphadenitis, osteomyelitis, tuberculid (erythema induratum, lichen scrofulosorum, and papulonecrotic tuberculid), and disseminated infection have been reported as the adverse events following BCG vaccination. Kawasaki disease (KD) is an acute, febrile, and systemic vasculitis primarily occurring in infants and young children. The incidence of KD is different among ethnic groups, and the highest incidence is reported in Japan (239/100,000 < 5 y of age). The most serious complication is coronary arterial lesion (CAL). Intravenous immunoglobulin (IVIG) and oral aspirin are effectively used during the acute phase of KD to reduce inflammation, particularly CAL. Prior to the introduction of IVIG, 20–30% of cases progressed to CAL, with 2% of mortality rate. The etiology of KD is still unknown, however it may be caused by an infectious agent that precipitates an excessive auto-inflammation in genetically predisposed individuals. Additionally, the changes at the inoculation site of BCG, including erythema or ulceration, are often observed during the acute phase of KD. BCG triggers apoptosis of tumor cells and promotes T cell activation responsible for long-term anti-tumor defense. These suggest that BCG response may be connected with the pathophysiology of KD. Tuberculid including erythema induratum, lichen scrofulosorum, and papulonecrotic tuberculid, is one of the frequent adverse events of BCG vaccination. Affected patients present with dull red or bluish red nodules (erythema induratum), pin head-size, skin-colored, to erythematous lichenoid, firm, follicular or perifollicular papules (lichen scrofulosorum), and papulonodular lesions (papulonecrotic tuberculid). The skin lesions usually emerge from 10 d to 2 months after vaccination. The mechanism of tuberculid is considered the skin reactions against BCG vaccine and/or immune responses to degenerated dead bacilli or antigenic fragments, because the lesions are negative for bacteria. However, there is little information about the detailed pathophysiology of tuberculid. It is critical to distinguish tuberculid from disseminated BCG infection or cutaneous tuberculosis. Neither antibiotics nor anti-tuberculous therapy is needed for the treatment of tuberculid. There are no reports about a relationship between tuberculid and KD. We herein first report 2 infants who developed tuberculid during the convalescent phase of KD.

Patient presentation

Patient 1

A 5 month-old Japanese male was hospitalized because of 5-days' high fever, erythema of the trunk, and conjunctival hyperemia. On admission, he had redness of lip, and swelling of feet and hands. The previously healthy boy was born to healthy parents having unremarkable family history. He received BCG vaccination intradermally at the left upper limb one week before the onset of KD. Complete blood counts showed leukocytes 22.2 × 109 /L, hemoglobin 11.1 g/dL, and platelets 416 × 109 /L. Blood chemistries revealed increased levels of C-reactive protein (CRP) (1.31 mg/dL, reference range [rr]: 0.01–0.14), and normal levels of aspartate transaminase (AST) 31 U/L (rr: 13–33), alanine transaminase (ALT) 15 U/L (rr: 8–42), albumin 4.2 g/dL (rr: 3.7–5.2), and sodium138 mmol/L (rr: 135–148). Under the diagnosis of KD, IVIG (2 g/kg) and aspirin (30 mg/kg, p.o.) were started on the 5th day of illness. The treatment led to the defervescence promptly, and sheet-like desquamation on the 9th day, respectively. On the day 25, small papules in the face and trunks, along with redness and crust formation at the inoculation site of BCG were observed (Fig. 1a). Skin biopsy revealed infiltration of inflammatory cells, ulceration, and crust formation without granuloma and leukocytoclastic vasculitis (Fig. 2a and b). Both bacteriological examination from skin lesions and interferon-γ release assay (IGRA) against Mycobacterium tuberculosis were negative. These results suggested that he had papulonecrotic tuberculid associated with BCG inoculation. The skin lesions disappeared without antibiotic therapy over 2 months. His nails became whitish, and were peeled off 45 d after KD onset (Fig. 3a). These manifestations completely resoluted 73 d after the onset of KD. He is alive and well without CAL one year after the hospital discharge.
Figure 1.

Rash of cheek and BCG inoculation site on day 43 in patient 1 (a), and cheek (b) and BCG inoculation site (c) on day 23 of KD onset in patient 2.

Figure 2.

Histopathological finding of skin biopsy from patients 1 (H & E; a: × 100, b: × 400) and 2 (H & E; c: × 100, d: × 400).

Figure 3.

The changes of nails on day 45 of KD onset in patient 1 (a) and in convalescent phase KD of patient 2 (b).

Rash of cheek and BCG inoculation site on day 43 in patient 1 (a), and cheek (b) and BCG inoculation site (c) on day 23 of KD onset in patient 2. Histopathological finding of skin biopsy from patients 1 (H & E; a: × 100, b: × 400) and 2 (H & E; c: × 100, d: × 400). The changes of nails on day 45 of KD onset in patient 1 (a) and in convalescent phase KD of patient 2 (b).

Patient 2

A 5 month-old Japanese male was hospitalized because of fever, redness at the BCG inoculation site, and redness of the lips. The previously healthy boy was born to healthy parents having unremarkable family history. He received BCG vaccination intradermally at the left upper limb before 6 weeks of the KD onset. On admission, he showed neither redness nor ulceration at BCG inoculation site. Complete blood counts showed leukocytes 14.4 × 109 /L, hemoglobin 10.4 g/dL, and platelets 274 × 109 /L. Blood chemistries revealed increased levels of AST 298 U/L (rr: 12–34) and ALT 61 U/L (rr: 5–43), CRP (18.14 mg/dL, rr: 0.01–0.14), and procalcitonin (1.58 ng/mL, rr: 0.00–0.10), low levels of sodium (132 mmol/L, rr: 137–147). On the day 4th of illness, he had conjunctival hyperemia, erythema of the trunk of the body, and swelling of feet and hands. Under the diagnosis of KD, IVIG (2 g/kg) and oral aspirin (30 mg/kg) were started on the 5th day of illness, but not led to the defervescence. Repeated IVIG on the 7th day of illness led to the complete resolution of KD symptoms. On the 10th day of KD, erythema in bilateral cheeks and blood clot and crust formation at the inoculation site of BCG were observed (Fig. 1b and c). Skin biopsy revealed infiltration of inflammatory cells, acanthosis, and epithelioid granuloma without caseous necrosis (Fig. 2c and d). Both bacteriological examination from skin lesions and IGRA were negative. These results suggested that he had lichen scrofulosorum. The skin lesions were gradually disappeared without administration of antibiotics over 2 months. His nails changed during tuberculid (Fig. 3b). He is alive and well without CAL one year after the hospital discharge.

Discussion

Skin complications including tuberculid are occasional adverse events of BCG vaccination. The incidence of tuberculid was extremely low, because the infants with tuberculid after BCG vaccination were reported to be 10–20 per 1 million inoculations in Japan. In our infants, the onsets of tuberculid were observed 10 d (patient 1) or 24 d (patient 2) after onset of KD. Redness, crust formation, and ulceration of BCG inoculation site are occasionally observed during acute phase in KD patients. The mechanism of changes at BCC inoculation sites remains unclear, however Siresi, et al. reported that T cell activation, and cross-reactivity between specific epitopes of mycobacterial and human Heat Shock Protein (HSP) may be involved in the changes of BCG inoculation site. In present cases, subsequent immune activation of KD might be a trigger of the onset of tuberculid. The changes at BCG inoculation site in young infants with KD could be linked to the pathophysiology of tuberculid. Both present cases received BCG vaccination 1.5 months (patient 1) or one week (patient 2) before the onset of KD, respectively. The relationship between the development of KD and vaccination is controversial. Previous reports have shown that KD was developed after the vaccinations of BCG, diphtheria–pertussis–tetanus (DPT), hepatitis A, hepatitis B, influenza, and rotavirus. On the other hand, vaccinations do not increase the risk of KD . In our infants, we could not prove the relationship between BCG inoculation and the onset of KD. Both infants with tubeculid showed changes of the color and hypertrophy of nails and their nails were peered off since the convalescent phases of KD, as shown in Figure 3. There are no reports about changes of the nails in infants with tuberculid. The mechanism of the nail changes in patients with tuberculid with KD is still unknown. However, it may be similar to sheet-like desquamation in KD patients, because they started after the convalescent phase of KD. These nail changes may be a specific symptom in infants with tuberculid associated with KD. There have been several reports about tuberculid after BCG vaccination. All children with tuberculid after BCG were reported to be previously healthy. On the other hand, disseminated BCG infection, which we need to distinguish from tuberculid, often appears under the impaired immune system. The patients' age were 3, 6, 6, 8, 9, 9 month-old, 2 and 7 year-old, respectively. In Japan, children generally received BCG vaccination before 1 y old. In addition, 80% of KD cases occur between the ages 6 months and 4 y. Our observations in these cases suggested a possible association among the age of BCG vaccination, the KD onset, and the development of tuberculid. We herein first report two 5-month-old infants with tuberculid after resolution of KD symptoms. The present patients suggest there may be relationships between the onset of tuberculid and the pathophysiology of KD.
  24 in total

1.  Lichen scrofulosorum-like eruption localized to multipuncture BCG vaccination site.

Authors:  Y M Park; H Kang; S H Cho; B K Cho
Journal:  J Am Acad Dermatol       Date:  1999-08       Impact factor: 11.527

2.  Scrofuloderma following BCG vaccination.

Authors:  Mustafa Atasoy; Cihangir Aliağaoğlu; Teoman Erdem; Sevki Ozdemir; Akin Aktaş
Journal:  Pediatr Dermatol       Date:  2005 Mar-Apr       Impact factor: 1.588

Review 3.  Papular tuberculides post-BCG vaccination: case report and review of the literature in Japan.

Authors:  J Muto; K Kuroda; S Tajima
Journal:  Clin Exp Dermatol       Date:  2006-07       Impact factor: 3.470

Review 4.  Vasculitis as an adverse event following immunization - Systematic literature review.

Authors:  Caterina Bonetto; Francesco Trotta; Patrizia Felicetti; Graciela S Alarcón; Carmela Santuccio; Novilia Sjafri Bachtiar; Yolanda Brauchli Pernus; Rebecca Chandler; Giampiero Girolomoni; Robert D M Hadden; Merita Kucuku; Seza Ozen; Barbara Pahud; Karina Top; Frederick Varricchio; Robert P Wise; Giovanna Zanoni; Saša Živković; Jan Bonhoeffer
Journal:  Vaccine       Date:  2015-09-21       Impact factor: 3.641

Review 5.  Kawasaki disease: an evolving paradigm.

Authors:  Antonio Greco; Armando De Virgilio; Maria Ida Rizzo; Mario Tombolini; Andrea Gallo; Massimo Fusconi; Giovanni Ruoppolo; Giulio Pagliuca; Salvatore Martellucci; Marco de Vincentiis
Journal:  Autoimmun Rev       Date:  2015-04-13       Impact factor: 9.754

6.  Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007.

Authors:  Wei Hua; Hector S Izurieta; Barbara Slade; Ermias D Belay; Penina Haber; Rosemary Tiernan; Emily Jane Woo; John Iskander; M Miles Braun; Robert Ball
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

Review 7.  Cutaneous tuberculosis in children.

Authors:  Gomathy Sethuraman; Venkatesh Ramesh
Journal:  Pediatr Dermatol       Date:  2012-11-22       Impact factor: 1.588

8.  Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site.

Authors:  Ritei Uehara; Hiroshi Igarashi; Mayumi Yashiro; Yosikazu Nakamura; Hiroshi Yanagawa
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

9.  Kawasaki disease in an infant following immunisation with hepatitis B vaccine.

Authors:  Dan Miron; Daniel Fink; Philip J Hashkes
Journal:  Clin Rheumatol       Date:  2003-10-07       Impact factor: 3.650

Review 10.  Kawasaki Disease: A Clinician's Update.

Authors:  Nathan Jamieson; Davinder Singh-Grewal
Journal:  Int J Pediatr       Date:  2013-10-27
View more
  2 in total

1.  BCG and Kawasaki disease in Mexico and Japan.

Authors:  Luisa Berenise Gamez-Gonzalez; Hiromichi Hamada; Beatriz Adriana Llamas-Guillen; Miguel Ruiz-Fernandez; Marco Yamazaki-Nakashimada
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

2.  Combined IFN-β and PLT Detection Can Identify Kawasaki Disease Efficiently.

Authors:  Kan Huijuan; Dong Yaping; Wang Bo; Hou Miao; Qian Guanghui; Yan Wenhua
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.